NIBEC CO., LTD.

138610· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩17,750-3.90%

2026-06-19

Price Chart

NIBEC CO., LTD.-36.15%

Financials

Investment Metrics(as of 2026-06-19)

Metric	Value
Size
Market Cap	201.78B KRW
Revenue	32.34B KRW
Net Income	-1.12B KRW
Total Assets	63.61B KRW
Net Assets	47.02B KRW
Employees	96
Value
P/B	4.29x
P/S	6.24x
EV/EBITDA	948.10x
FCF Yield	2.15%
Profitability
ROE	-2.39%
ROA	-1.76%
Op. Margin	0.64%
Revenue Growth	-6.69%
Financial Health
Debt Ratio	135.28%
Total Debt	17.41B KRW
FCF	4.33B KRW
Cash	22.60B KRW
Current Ratio	3.35x
Net Debt/EBITDA	-25.06x
Performance
1Y Return	-36.15%
1M Return	-14.46%
From 52W High	-67.31%
1Y MDD	-66.67%
Trading
Volume	49,474 shares
Foreign Own.	3.85%
Per Share
EPS	646 KRW
BPS	4,136 KRW

Company Info

CEO 정종평

Employees 96

Founded 2004

HQ 충청북도 진천군, KR

NIBEC, established in 2004, was founded to commercialize research from the Seoul National University College of Dentistry's Intelligent Bio-Interface Engineering Research Center. The company develops peptide-based drugs, convergence biomaterials, and protein engineering technology-based drugs, leveraging peptide-based drug delivery systems and biomaterial technology for tissue regeneration. Its dental bio-regeneration materials are sold globally through Straumann and Nobel Biocare, having received NMPA sales approval in China in 2020. NIBEC is headquartered in Jincheon-gun, Chungcheongbuk-do.